CTNM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Contineum Therapeutics Inc (CTNM) is not a strong buy at this moment for a beginner investor with a long-term focus. While the stock has some positive catalysts, such as an analyst price target increase and upcoming clinical catalysts in 2026, the company's financial performance remains weak with negative net income and EPS. Technical indicators are neutral to slightly bullish, but no significant trading signals or recent news events suggest an immediate opportunity. Given the user's preference for long-term investment, it would be prudent to wait for stronger financial performance or clearer positive momentum.
The MACD is slightly positive (0.031), RSI is neutral at 43.368, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 12.402, and resistance is at 13.937. However, the stock is trading below the pivot level of 13.17, indicating limited upward momentum.
Analyst price target raised from $14 to $20 with an Outperform rating. Upcoming clinical catalysts in 2026.
Weak financial performance with negative net income (-$15.16M) and declining EPS (-12.5% YoY). No recent news or significant trading trends from hedge funds, insiders, or Congress.
In Q4 2025, revenue remained at $0 with no growth. Net income improved slightly (-4.06% YoY), but EPS declined (-12.5% YoY). Gross margin remains at 0.
Baird analyst Charles Moore raised the price target to $20 from $14 and maintained an Outperform rating. The update reflects optimism about clinical catalysts in 2026.
